Scientific Advisory Board
William Andrews, Ph.D.
Anthony Atala, M.D.
David L. Ayares, Ph. D.
L. Stephen Coles, M.D., Ph.D.
Aubrey D.N. J. de Grey, Ph.D.
Michael B. Fossel, Ph.D.
Robert A. Freitas Jr, M.D.
Leonid A. Gavrilov, Ph.D.
Ben Goertzel, Ph.D.
Challa Kumar, Ph.D.
Graham Peter Pawelec, Ph.D.
Michael R. Rose, Ph.D.
Stephen R. Spindler, Ph.D.
Bryant Villeponteau, Ph.D.
Richard Weindruch, Ph.D.
Avi Roy, Ph.D.
William Andrews, Ph.D.
Dr. William H. Andrews has worked in the biotech industry for 38 years, focusing the last 25 years on finding ways to extend human lifespan through the intervention of telomere shortening in human cells.
Dr. Andrews earned his Ph.D. in Molecular and Population Genetics at the University of Georgia in 1981. He was a Senior Scientist at Armos Corporation and Codon Corporation, Director of Molecular Biology at Codon and at Geron Corporation, and Director of Technology Development at EOS Biosciences. He is presently the founder, President and CEO of Sierra Sciences, a biotech company in Reno, Nevada focused exclusively on finding drugs that will transiently induce the expression of endogenous telomerase in human cells. Sierra Sciences has already identified more than fifty such drugs and is presently characterizing their mechanism of action.
While Director of Molecular Biology at Geron Corporation, Dr. Andrews was one of the principal discoverers of both the RNA and protein components of human telomerase and was awarded 2nd place as “National Inventor of the Year” in 1997 for this work. He is presently a named inventor on 42 US issued telomerase patents.
Anthony Atala, M.D.
Anthony Atala, MD, earned his medical degree from the University of Louisville School of Medicine. He completed his residency at the University of Louisville and a fellowship at Harvard Medical School/Boston’s Children’s Hospital. He joined Wake Forest Baptist in 2006 as the founding director of the Wake Forest Institute for Regenerative Medicine and chair of the Department of Urology.
As director of the Institute for Regenerative Medicine, Atala oversees a team of more than 400 researchers who are dedicated to developing cell therapies and engineering replacement tissues and organs. They are currently working on therapies for more than 40 different areas of the body. From developing a new treatment for hemophilia to engineering muscle, bone and tendons for reconstructive surgery, the institute focuses on developing new therapies to improve patients’ lives.
Atala also directs the Armed Forces Institute of Regenerative Medicine, a federally funded effort to apply regenerative medicine. Related projects underway include engineering blood vessels, developing treatments to heal wounds and engineering replacement tissues for devastating pelvic injuries.
Atala is a recipient of many awards, including the Christopher Columbus Foundation Award, which is bestowed on a living American who is currently working on a discovery that will significantly affect society, and the World Technology Award in Health and Medicine, presented to individuals achieving significant, lasting progress. In 2011, he was elected to the Institute of Medicine of the National Academy of Sciences and was inducted to the National Academy of Inventors as a Charter Fellow in 2014.
He was named by Scientific American as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue and organ regeneration. His work was listed as Time Magazine’s top 10 medical breakthroughs of the year and Discover Magazine’s Number 1 Top Science Story of the Year in the field of medicine in 2007. In 2009 Atala was featured in U.S. News & World Report as one of 14 Pioneers of Medical Progress in the 21st Century, and his work was listed by Smithsonian Magazine as one of 40 things to know about the next 40 years in 2010. In 2015, he was named by Scientific American as one of the world’s most influential people in biotechnology.
Atala has led or served on several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium and the National Cancer Institute’s Advisory Board.
More than 12 applications of technologies developed in Atala’s laboratory have been used clinically. He is the editor of 14 books, including Principles of Regenerative Medicine, Foundations of Regenerative Medicine, Methods of Tissue Engineering and Minimally Invasive Urology. He has published more than 500 journal articles and has applied for or received over 250 national and international patents.
He is currently professor and chair of the Department of Urology at Wake Forest Baptist Medical Center, directs the Wake Forest Institute for Regenerative Medicine and specializes in: Urology, Microsurgery, Biomaterials, Stem cell therapies and Tissue engineering.
David L. Ayares, Ph.D.
Dr. Ayares is currently President & CEO, Revivicor, Inc. Prior to the formation of Revivicor, Dr. Ayares was Vice President of Research and COO for PPL Therapeutics Inc., where he has directed research since 1997. PPL has a diverse product development pipeline focussed on:
- Development of genetically modified pig organs, and cells, for xenotransplantation applications,
- Stem cell therapies,
- Production of human therapeutic proteins in the milk of transgenic livestock, and
- Development of human polyclonal antibodies in genetically modified cattle for biological warfare countermeasures. PPL is the World leader in animal cloning technology, responsible for “Dolly” the cloned sheep, and the first successful cloning of pigs. In addition the company has strong research efforts in cell biology, molecular biology, embryology, and transgenic technology.
Dr. Ayares has been directing research activities at PPL since 1997. Previously worked for 7 years in the pharmaceutical industry; 2 years (1995-96) as a Senior Scientist and Molecular Biology Manager in the Gene Therapy Division at Baxter Healthcare, working on the development of adenovirus and AAV-based vector systems for in vivo gene therapy applications; and 5 years (1990-1995) at Abbott Laboratories, as Head of Transgenic Technology, developing transgenic mouse models for pharmaceuticals testing. Doctoral research at the University of Illinois Medical Center (1982-1987), and post-doctoral research, in the Dept. of Biology at M.I.T. (1987-1990), focused on the study of homologous recombination and DNA repair mechanisms in mammalian systems.
Robert Bradbury (In Memoriam)
Mr. Bradbury attended Harvard University where he majored in Applied Mathematics. His work in the software industry included managing the largest commercial minicomputer installations in New York City in the late 1970’s and playing key roles in the success of Oracle Corporation in the 1980’s. He studied microbiology and biochemistry at the University of Washington. In the early 1990’s he founded Aeiveos Corporation which initiated and supported a number of research studies related to the molecular biology of aging in the Russian Federation. An Aeiveos, Tako Ventures partnership was formed during 1996 and 1997, the 2nd largest company conducting aging research, after Geron. He is currently CEO of Robiobotics.
Robiobotics will focus on developing whole genome engineering. Its emphasis will be to utilize bioinformatics and biotechnologies resulting from the Human Genome Project in synergistic ways to enable the rapid and inexpensive development of robust therapies for aging related diseases as well as accelerating the development of molecular nanotechnology.
L. Stephen Coles, M.D. Ph.D.
Dr. Coles is a Co-Founder and Director of the Los Angeles Gerontology Research Group and Director of the Supercentenarian Research Foundation. He is a Director of the Los Angeles Chapter of Physicians for Social Responsibility (PSR). He served as an Assistant Researcher in the Department of Surgery at the UCLA David Geffen School of Medicine, a Visiting Scholar in the UCLA Department of Computer Science, and is currently a Lecturer in the UCLA Department of Chemistry and Biochemistry (Molecular Biology Institute) as well as a Visiting Scholar in the Stanford University Department of Developmental Biology. Dr. Coles is the author or co-author of over 154 scientific papers and holds two patents.
He received his B.S. in Electrical Engineering from Rensselaer Polytechnic Institute in Troy, New York, his Master’s in Mathematics from the Carnegie Institute of Technology, and his Ph.D. in Systems and Communication Sciences from Carnegie-Mellon University in Pittsburgh, Pennsylvania. After attending Stanford University Medical School, Dr. Coles completed his Clinical Internship in OB/GYN at the Jackson Memorial Hospital of the University of Miami School of Medicine. After teaching at UC Berkeley, Dr. Coles served as a Lecturer at UCLA, USC, and the California Institute of Technology.
Aubrey D.N.J. de Grey, Ph.D.
Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK and Mountain View, California, USA, and is the Chief Science Officer of SENS Foundation, a California-based 501(c)(3) charity dedicated to combating the aging process. He is also Editor-in-Chief of Rejuvenation Research, the world highest-impact peer-reviewed journal focused on intervention in aging.
He received his BA and Ph.D. from the University of Cambridge in 1985 and 2000 respectively.
His original field was computer science, and he did research in the private sector for six years in the area of software verification before switching to biogerontology in the mid-1990s. His research interests encompass the characterization of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. He has developed a possibly comprehensive plan for such repair, termed Strategies for Engineered Negligible Senescence (SENS), which breaks aging down into seven major classes of damage and identifies detailed approaches to addressing each one. A key aspect of SENS is that it can potentially extend healthy lifespan without limit, even though these repair processes will probably never be perfect, as the repair only needs to approach perfection rapidly enough to keep the overall level of damage below pathogenic levels. Dr. de Grey has termed this required rate of improvement of repair therapies longevity escape velocity.
Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.
Michael B. Fossel, M.D., Ph.D.
Author of a major book on Telomerase Therapy, which the Wall Street Journal named as one of the five best science books of the year, and working to bring telomerase therapy to human trials, Michael Fossel, M.D., Ph.D. (born 1950, Greenwich, Connecticut) was a professor of clinical medicine at Michigan State University for almost 30 years and still teaches Biology of Aging as a university professor.
Founder and former editor-in-chief of Rejuvenation Research, he is best known for his views on telomerase therapy as a possible treatment for cellular senescence and human age-related disease. Dr. Fossel has appeared on many major news programs to discuss aging and regularly on National Public Radio (NPR). He is also a respected lecturer, author, and physician.
Prior to earning his M.D. at Stanford Medical School, Fossel earned a joint B.A. (cum laude) and M.A. in psychology at Wesleyan University and a Ph.D. in neurobiology at Stanford University. He is also a graduate of Phillips Exeter Academy. After graduating from medical school in 1981, he was awarded a National Science Foundation fellowship and taught at Stanford University Medical School.
Dr. Fossel has lectured at the National Institute for Health, the Smithsonian Institution, and at various other universities and institutes around the world. Fossel is a fellow of the American College of Emergency Physicians, a member of the American Association for the Advancement of Science, the Gerontological Society of America, the American Society on Aging, and the American Geriatrics Society, and served on the board of directors for the American Aging Association, as well as their executive director.
Fossel has written numerous articles on aging and ethics for the Journal of the American Medical Association and In Vivo, and he published a book titled Reversing Human Aging in 1996. The book garnered favorable reviews from mainstream newspapers as well as Scientific American and has since been published in six languages. His magisterial academic textbook Cells, Aging, and Human Disease was published in 2004 by Oxford University Press. His latest book, Electronic Health Records: Strategies for Long-Term Success was published in 2013 by Health Administration Press. His new book, tentatively titled Telomerase Therapy, is now in press and due for publication in 2015.
Since his days teaching at Stanford University, Fossel has studied aging from a medical and scientific perspective with a particular emphasis on premature aging syndromes such as progeria, and since at least 1996 he has been a strong and vocal advocate of experimenting with telomerase therapy as a way of treating diseases, disorders, and syndromes such as progeria, Alzheimer’s disease, atherosclerosis, osteoporosis, cancer, AIDS, and organ senescence (i.e., aging). However, he is careful to qualify his advocacy of telomerase therapy as being a potential treatment for these conditions rather than a “cure for old age” and a panacea for age-related medical conditions, albeit a potential treatment that could radically extend the maximum human life span and reverse the aging process in most people. Specifically, Fossel sees the potential of telomerase therapy as being a highly effective point of intervention in a wide variety of medical conditions.
Robert A. Freitas Jr., J.D.
Dr. Freitas is Senior Research Fellow at the Institute for Molecular Manufacturing (IMM) in Palo Alto, California, and was a Research Scientist at Zyvex Corp. (Richardson, Texas), the first molecular nanotechnology company, during 2000-2004. He received B.S. degrees in Physics and Psychology from Harvey Mudd College in 1974 and a J.D. from University of Santa Clara in 1979.
Dr. Freitas co-edited the1980 NASA feasibility analysis of self-replicating space factories and in 1996 authored the first detailed technical design study of a medical ever published in a peer-reviewed mainstream biomedical journal. More recently, Freitas is the author of Nanomedicine, the first book-length technical discussion of the potential medical applications of molecular nanotechnology and medical nanorobotics; the first two volumes of this 4-volume series were published in 1999 and 2003 by Landes Bioscience.
His research interests include: nanomedicine, medical nanorobotics design, molecular machine systems, diamond mechanosynthesis (theory and experimental pathways), molecular assemblers and nanofactories, and self-replication in machine and factory systems. He has published 27 refereed journal publications and several contributed book chapters, and most recently co-authored Kinematic Self-Replicating Machines (2004), another first-of-its-kind technical treatise.
Leonid A. Gavrilov, Ph.D.
Leonid A. Gavrilov is a Senior Research Scientist for the Center on the Demography and Economics of Aging with NORC at the University of Chicago. He also is a faculty member in the Center for East European and Russian/Eurasion Studies at the University of Chicago.
Gavrilov specializes in the biodemography of aging and longevity, mathematical modeling of aging and mortality, population aging and the demography of the Former Soviet Union.
Gavrilov is currently the principal investigator for Biodemography of Exceptional Longevity in the United States, a study funded by the National Institute on Ageing (NIA) in which he is investigating biological and social correlates for people that live over 100. Other studies funded by the NIA include Middle-Life Physical Markers, Socioeconomic Status and Exceptional Longevity: An Exploratory Study of a New Data Resource, and the Biodemography of Human Longevity – Training Program. Both projects focused on aging and acted as pre-cursors to Gavrilov’s current work with Biodemography of Exceptional Longevity in the United States. Gavrilov works at NORC with long-time colleague Natalia S. Gavrilova, Ph.D., and has developed a number of joint publications and projects with her.
Before coming to the United States, Gavrilov held senior research positions in Moscow (Russia) at the A.N. Belozersky Institute, Moscow State University and at the Institute for Systems Analysis, Russian Academy of Sciences.
In demand as a speaker at conferences, meetings, and workshops internationally, Gavrilov’s work has been featured in a variety of publications, such as Population Research and Policy Review, North American Actuarial Journal, Social Biology, Journal of Theoretical Biology, Population, Demographic Research, Perspectives in Biology and Medicine, Human Biology, Handbook of the Biology of Aging (Sixth Edition), and many more. He serves on several editorial boards, including Experimental Gerontology (Elsevier Science, Inc.), Gerontology (Karger), Rejuvenation Research (Mary Ann Libert Inc. Publishers), Advanced Science Letters (American Scientific Publishers) and Theoretical Biology and Medical Modelling (BioMed Central).
The Moscow Society of Naturalists, the International Science Foundation, the European Union and others have honored and recognized Gavrilov for his ongoing contributions to research in aging. He is a member of the Population Association of America and a Fellow of the Gerontological Society of America, where he has served on the Executive Committee on Biological Sciences and the Task Force on Organizational Technology and Computers. He is currently a Convener for the Gerontological Society of America Interest Group “Societal Implications of Delayed Aging.”
Ben Goertzel, Ph.D.
Ben Goertzel, Ph.D. is SIAI Director of Research, responsible for overseeing the direction of the Institute’s research division. He is also chief science officer and acting CEO of Novamente, a software company aimed at creating applications in the area of natural language question-answering. He also oversees Biomind, an AI and bioinformatics firm that licenses software for bioinformatics data analysis to the NIH’s National Institute for Allergies and Infectious Diseases and CDC. He is chair of the Artificial General Intelligence Research Institute. Previously, he was founder and CTO of Webmind, a 120+ employee thinking-machine company.
Ben has over 70 publications, concentrating on cognitive science and AI, including Chaotic Logic: Language, Thought, and Reality from the Perspective of Complex Systems Science, Creating Internet Intelligence: Wild Computing, Distributed Digital Consciousness, and the Emerging Global Brain, Artificial General Intelligence (edited with Cassio Pennachin), The Hidden Pattern: A Patternist Philosophy of Mind, The Structure of Intelligence: A New Mathematical Model of Mind Advances in Artificial General Intelligence: Concepts, Architectures and Algorithms edited with Pei Wang, The Path to Posthumanity: 21st Century Technology and Its Radical Implications for Mind, Society and Reality, and coauthored Probabilistic Logic Networks: A Comprehensive Conceptual, Mathematical and Computational Framework for Uncertain Inference.
Watch Introduction to Artificial General Intelligence (AGI) (10 minutes), AGI and the Singularity (43 minutes), Novamente AGI Project (57 minutes), Ensuring Responsible AGI (82 minutes/panel), Bottlenecks / How Soon to AGI (68 minutes/panel), Ten Yrs to the Singularity? (42 minutes), AGI, What are the Risks? (41 minutes/panel), AGI vs Narrow AI (41 minutes), and AGI and Cybernetic Immortality (48 minutes).
Ben earned a Ph.D. in mathematics from Temple University in 1989, and has held several university positions in mathematics, computer science, and psychology, in the US, New Zealand, and Australia.
Bryant Villeponteau, Ph.D.
Dr. Villeponteau has 30 years of scientific leadership experience and about 60 scientific journal and patent publications. Dr. Villeponteau holds a B.A. in Economics, a M.A. in Biostatistics, and a Ph.D. in Molecular Biology from UCLA. He was Assistant Research Chemist in the Department of Chemistry and Biochemistry at UCLA for 4 years and Assistant Professor of Biological Chemistry at the University of Michigan Medical School for 6 years.
Dr. Villeponteau then led a research group at Geron Corporation for 4.5 years, where he was the lead inventor in cloning human telomerase, thereby winning the Distinguished Inventor Award for the 2nd best US patent of 1997. As the Champion of Telomerase Therapeutics at Geron, he also worked on human stem cells, which were pioneered by Geron in the 90s. Dr. Villeponteau then joined HealthSpan Sciences, Inc. as VP and later served as CEO for three years. For the next 8 years, he served as a VP/consultant for Sierra Sciences.
From September of 2008 to present, Dr. Villeponteau has been the VP of R & D of Genescient Corporation. Dr. Villeponteau also cofounded Centagen, incorporated in January of 2009, and Life Code LLC in October of 2010, which has marketed a successful supplement that doubles
maximum lifespan in model animals and supports stem cells and their niches.
Ray Kurzweil has been described as “the restless genius” by the Wall Street Journal, and “the ultimate thinking machine” by Forbes. Inc. magazine ranked him #8 among entrepreneurs in the United States, calling him the “rightful heir to Thomas Edison,” and PBS included Ray as one of 16 “revolutionaries who made America,” along with other inventors of the past two centuries.
As one of the leading inventors of our time, Ray was the principal developer of the first CCD flat-bed scanner, the first omni-font optical character recognition, the first print-to-speech reading machine for the blind, the first text-to-speech synthesizer, the first music synthesizer capable of recreating the grand piano and other orchestral instruments, and the first commercially marketed large-vocabulary speech recognition. Ray’s web site Kurzweil AI.net has over one million readers.
Among Ray’s many honors, he is the recipient of the $500,000 MIT-Lemelson Prize, the world’s largest for innovation. In 1999, he received the National Medal of Technology, the nation’s highest honor in technology, from President Clinton in a White House ceremony. And in 2002, he was inducted into the National Inventor’s Hall of Fame , established by the US Patent Office .
He has received twelve honorary Doctorates and honors from three U.S. presidents.
Ray has written five books, four of which have been national best sellers. The Age of Spiritual Machines has been translated into 9 languages and was the #1 best selling book on Amazon in science. Ray’s latest book, The Singularity is Near, which went into its fourth printing after two months, was the fourth best-selling science book of 2005 according to Amazon despite coming out late in the year.
Graham Peter Pawelec, Ph.D.
Graham Pawelec received an MA in Natural Sciences in 1978 and a PhD in Transplantation Immunology in 1982 from the University of Cambridge, UK, and the Dr. habil and Venia Legendi from the University of Tübingen, Germany, where he became Professor of Experimental Immunology in 1997. From 1999 to 2017 he led the Tübingen Ageing and Tumour Immunology (TATI) group within the Second Department of Internal Medicine, University of Tübingen Hospitals System. He remains affiliated part-time with the department at the Center for Medical Research, University of Tübingen. He is currently affiliated with the Cancer Solutions Program, Health Sciences North Research Institute of Canada, Sudbury, ON, and is a Visiting Professor at Nottingham Trent University, UK, King´s College London, London, UK, and is an Honorary Professor at Manchester University, UK.
He is Co-Editor-in Chief of Cancer Immunology Immunotherapy, and is Deputy or Associate Editor in several other journals. He has authored or co-authored 270 peer-reviewed original articles from a total of 486 PubMed-listed publications, has edited 3 books and co-edited several others (as of December 2018 in Google Scholar, 24,006 citations, H-index 87). He has coordinated three European Union collaborative programs on immunosenescence (EUCAMBIS, ImAginE and T-CIA) and two on cancer vaccine research (EUCAPS, ESTDAB). He was a member of the Sanofi-Pasteur-MSD and Sanofi-Aventis Advisory Boards on Immunosenescence and Vaccination, and of the WHO Initiative for Vaccine Research Advisory Board on the Impact of Ageing on Vaccination.
His research interests remain centered on vaccination, cancer immunology and immunotherapy, and immunogerontology.
Michael R. Rose, Ph.D.
Dr. Rose has been a professor of biology at the University of California, Irvine, since 1990, and since 2006, he’s also been the Director of the Network for Experimental Research of Evolution (NERE). He received his Ph.D. in biology in 1979 from the University of Sussex, and in the same year, he followed a NATO Science Fellowship, which led him to the University of Wisconsin – Madison, where he worked at the Department of Genetics with James F. Crow. It was during this time that he focused his work on the concept of “antagonistic pleiotropy”—a phenomenon in which evolution selects for genes that cause beneficial traits early in life and deleterious traits later in life due to their positive effects on reproductive fitness. While antagonistic pleiotropy was first proposed by George C. Williams in 1957 as an evolutionary explanation for senescence, its name was coined by Dr. Rose.
Dr. Rose continued pursuing his interest in aging research even after that, particularly postponed aging, studying the relationships between physiology and evolution. In 1991, he published “Evolutionary Biology of Aging”, a book that offered an entirely new view of aging. The importance of this text was such that the journal Evolution described it as a milestone marking the “after Rose” age of gerontology. Many other books and publications followed that one, including Darwin’s Spectre” and “Methuselah Flies”, a compendium of the research findings of his laboratories.
Besides aging, Dr. Rose’s research interests include human evolution, experimental evolution, the evolution of sex, Drosophila, and biological immortality. He is the recipient of several awards, including the Excellence in Teaching Award (UCI Biological Sciences) and the Busse Prize (World Congress of Gerontology), which he received in 1996 and 1997, respectively.
Stephen R. Spindler, Ph.D.
Professor of Biochemistry and former Chairman of the Department of Biochemistry at the University of California, Riverside. For the past 25 years, he has studied the molecular basis for the disease preventing, life-span extending effects of caloric restriction. His work has been supported by grants from the National Institutes of Health, National Science Foundation, American Cancer Society, as well as private and corporate donors.
He has served as a member of National Institutes of Health scientific review and advisory committees. He is using genechip technology to discover compounds which delay or prevent the onset of age-related diseases such as cancer, diabetes, and cardiovascular disease.
Challa Kumar, Ph.D.
Challa Kumar is Group Leader for Nanofabrication at the Center for Advanced Microstructures and Devices (CAMD) at Louisiana State University in Baton Rouge, Louisiana. He is the Editor of a ten volume book series on ‘Nanotechnologies for the Life Sciences’ published by Wiley-VCH. He is also the founding Editor-in-Chief of Journal of Biomedical Nanotechnology published by American Scientific Publishers. He has authored over thirty scientific publications and holds over ten patents either granted or pending.
He received his Ph.D degree in Synthetic Organic Chemistry from Sri Sathya Sai Institute of Higher Learning, Prashantinilyam, India. He was a post doctoral fellow at the Max-Planck Institute for Biochemie, Munich, Germany followed by eight years of experience working in different chemical industries in various capacities.
Richard Weindruch, M.D.
Dr. Richard Weindruch is a co-founder of LifeGen Technologies, a genomics company that is discovering the genes associated with aging. He is a Professor Emeritus, Department of Medicine, University of Wisconsin – Madison. Dr. Weindruch has studied the retardation of aging by caloric restriction for 38 years.
Dr. Weindruch earned his bachelor’s degree and master’s degree in biology at the University of Illinois and his doctoral degree in experimental pathology at UCLA. He has authored two books and published more than 175 scientific articles. In 1988, Dr. Weindruch co-authored “The Retardation of Aging and Disease by Dietary Restriction,” which is widely regarded as the founding text for this growing field.
Dr. Weindruch has received several awards for his research including the 1998 Kleemeir Award from the Gerontological Society of America, the 2000 Nathan Shock Award from the National Institute on Aging (NIA), and the 2000 Glenn Award from the Paul Glenn Foundation. He is co-directing a large NIA-funded study to determine whether caloric restriction retards the aging process in primates. He is also investigator on other NIA-funded projects.
Avi Roy, Ph.D.
Avi Roy CSO is the President of the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population. Avi is an Oxford based biomedical scientist, with degrees in biomedical science and computer science. His PhD research involved the rejuvenation of human skin using small molecules, and identifying accurate biomarkers of aging. Avi rejuvenated the skin cells taken from 80 year old patients by transplanting the mitochondria taken from 16 year old skin cells. Using transcriptomics, proteomics and computational biology Avi identified the pathways involved in the rejuvenation of skin, and ever since has been screening small molecules to replicate the regenerative process. His research has resulted in an advanced protocol for screening drugs that have geroprotective properties, which has identified twelve novel geroprotective drugs. Over the past eight years Oxford has been Avi’s home where he has headed the Oxford University Scientific Society, the world’s oldest student scientific organization. He also co-founded the Oxford Transhumanism and Emerging Technology Society, and the Oxford University Synthetic Biology Society. He is always involved in public dissemination of science and has organised over 370 talks, chaired 8 conferences and hosted 28 nobel prize winners. Recently, Avi has launched the Big Data Science in Medicine Conference series, the first conference series of its kind in Europe; and the Longevity Reporter, which has rapidly become the premier source for news about health and longevity.